Nuformix excited as it moves focus to NXP002 and NXP004 programmes

Nuformix plc (LON:NFX) Executive Director Dan Gooding joins DirectorsTalk to discuss an update on its NXP001 exclusive licensing agreement.

In this interview Dr Dan Gooding outlines what the revised agreement covers, explains what it means for Nuformix and how it will benefit from NXP001 now and in the future, progressing its core NXP002 and NXP004 programmes and how Dan sees the outlook for the company.

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
X
LinkedIn
Nuformix plc

More articles like this

Nuformix plc

Nuformix Plc Receives Second NXP001 Milestone Payment from Oxilio

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced that the Company has achieved the second milestone according to its updated NXP001 exclusive licensing agreement with Oxilio

Nuformix plc

Nuformix hosting online Q&A session on 13 June 2023

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced that the Company’s Executive Director, Dr Dan Gooding, will be hosting an online Q&A session at 5.30

Nuformix plc

Nuformix appoints Kreston Reeves as auditor

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced the appointment of Kreston Reeves LLP as auditor to the Company. The appointment of Kreston Reeves

Nuformix plc

Nuformix delighted with NXP002 study results

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced the following update regarding the Company’s NXP002 programme, a proprietary new form of tranilast, being developed as a

Nuformix plc

Nuformix updates on the NXP002 programme for treatment of IPF

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced the following update regarding the Company’s NXP002 programme, a proprietary new form of tranilast, being developed as a

Nuformix plc

Nuformix further evaluating NXP002 combination therapies now underway

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced the following update regarding the Company’s NXP002 programme, a proprietary new form of tranilast, being developed as a